Fitzpatrick LR, O’Connell R, Talbott G et al. A novel ROR-gamma T inhibitor (VPR-254) attenuates key parameters of innate immune colitis in mice. Digestive Disease Week annual meeting, Chicago IL, May 2017.

Abstract: Injection of an agonistic CD40 monoclonal antibody to T and B cell-deficient mice induces an innate inflammatory response with colonic inflammation. This colitis is dependent on ROR-γT and various cytokines (IL-23, IL-17, IL-22 and GM-CSF [Pearson et al., eLIFE, 2015]. Therefore, we hypothesized that this colitis would be attenuated by oral treatment with a novel ROR-gamma T inverse agonist (VPR-254). Methods: Female scid mice were injected by the ip route with 12 mg/kg of anti-CD40 monoclonal antibody to induce innate acute colitis. On the same day (study day 0), mice (n = 10 per group) were treated (days 0–7) with vehicle, VPR-254 (50 mg/kg, po, bid), or ip with anti-IL-12 p40 antibody (0.5mg/mouse, on study days 0 and 3). A naïve group of four mice served as the non-colitis control group. Mice were euthanized on study day 7. Efficacy evaluations included: animal body weight, colon weight and length measurements, colonic histology (12 point severity scale, on coded slides) and the level of colonic GM-CSF (determined by ELISA). Colonic tissue samples (n = 4 per group) were also processed for immunohistochemistry, utilizing specific antibodies for IL-17A and GM-CSF. The percent areas of cytokine immunostaining in the mouse colon were determined with an online grid software program. Results: Vehicle control mice lost body weight (≈ 15%) during the study. VPR-254 modestly protected mice from weight loss; while anti-IL-12 antibody treated mice maintained their body weight throughout the study. Colonic weights (mg) were: 189±12 (naïve), 298±21 (vehicle), 248±12 (VPR-254) and 212±6 (anti-IL-12 antibody). Both drug treatments significantly reduced (p< 0.05) this morphometric parameter of colitis compared to vehicle treatment. Interestingly, VPR-254 treated mice had the longest colon length (p < 0.05 vs. vehicle) in this study. Colonic histology scores were: 2.6±0.2 (naïve), 9.0±0.5 (vehicle), 6.2±0.4 (VPR-254) and 3.7±0.3 (anti-IL-12 antibody). Both drug treatments significantly reduced (p< 0.05) this histological parameter of colitis compared to vehicle treatment. ELISA results showed that colonic GM-CSF antibody levels were significantly reduced in mice treated with VPR-254 (24% reduction), or anti-IL-12 (p40) (42% reduction), as compared to vehicle treatment. The mean percent areas of GM-CSF immunostaining were: 36±4 (naïve), 65±5 (vehicle), 56±7 (VPR-254) and 41±5 (anti-IL-12 ab, p<0.05 vs. vehicle). A somewhat similar pattern of immunostaining was found for IL-17A. There was a significant association (r = 0.704, p = 0.002) between colonic GM-CSF staining and histopathology scores. Summary: A novel ROR-γT Inhibitor (VPR-254), as well as an anti-IL-12 p40 antibody, reduced key parameters of innate immune colitis in mice. Conclusion: These results further support ROR-gamma T inhibition as a possible pharmacological approach for colonic inflammation.


Kreys ED, Frei CR , Villarreal SM, Bollinger MJ et al. Medication adherence and persistence of Dasatinib and Nilotinib in a national cohort of veterans. Managed Care Pharmacy Annual Meeting, Denver CO, March 2017.

Abstract: The introduction of tyrosine kinase inhibitor, imatinib, was a breakthrough in the treatment of CML that drastically improved outcomes. Medication adherence is essential to achieve these outcomes. Second-generation TKIs, dasatinib and nilotinib, are commonly used as second-line treatment after imatinib failure, yet studies comparing adherence between the two drugs have revealed conflicting results. Objective To compare treatment persistence and medication adherence between dasatinib and nilotinib as second-line treatment. Methods This observational study utilized internal Veterans Health Administration (VHA) databases for the time period of 10/1/2000-9/20/2012. The study included VHA beneficiaries, age 18-89 years, with ≥1 encounter at any of the VHA institution with a diagnosis code for CML (ICD-9 205.1x). Patients had to have filled ≥1 prescription of nilotinib or dasatinib as second-line treatment, defined as TKI treatment subsequent of previous treatment of one other TKI. Primary study endpoints included medication adherence, as measured by Proportion of Days (PDC), and treatment persistence in the first year of treatment. Appropriate level of adherence was defined as achieving PDC ≥80%. Persistence was evaluated using Kaplan-Meier analysis in conjunction with a log-rank test. Multivariable analyses were performed to control for pertinent confounding variables. Results As second line treatment 457 patients received dasatinib while 124 received nilotinib. The average PDC was 51% (±35%) for dasatinib-treated patients as compared to 47% (±34%) of nilotinib-treated patients, resulting in a mean difference of 4% (95% CI: -3.5 - 11.0%, p= 0.309). Thirty-three percent of the dasatinib-treated patients were deemed adherent during first-year of treatment relative to 28% of nilotinib-treated patients resulting in an adjusted odds ratio (OR) of 1.24 (95% CI: 0.78-1.95, p= 0.361). A Kaplan-Meier analysis did not demonstrate a statistically significant difference in time to discontinuation between dasatinib and nilotinib (p= 0.740). Forty-five percent of patients receiving dasatinib continued therapy beyond one year relative to 44% of patients receiving nilotinib resulting in an adjusted OR of 1.10 (95% CI 0.71-1.68, p= 0.680). Conclusion In this national cohort of VHA patients receiving dasatinib or nilotinib as second-line treatment, no significant differences in the persistence or adherence were identified.


Yadao MA, Kreys ED, Phung O. Trends in hospitalizations as a result of chemotherapy-induced adverse effects. Annual Conference of the Hematology/Oncology Pharmacy Association, Anaheim CA, March 2017.

Abstract: Chemotherapy often causes severe complications that may lead to hospitalizations and negatively affect clinical outcomes. Over time new treatments have been developed and guidelines have been updated to limit the negative impact of these complications. Objective: To evaluate the incidence and trends of hospitalizations as a result of certain chemotherapy-induced adverse effects among cancer patients. Methods: This was a retrospective cohort study that utilized the National Inpatient Sample database, within the Healthcare Cost and Utilization Project, to evaluate hospitalizations of cancer patients from 1997 to 2010 Hospitalizations were selected using ICD-9 diagnosis codes for aplastic anemia (284), neutropenia (288.00), nausea and vomiting (787.01 – 787.03), and pneumocystis (136.3). Cancer prevalence data, from the Surveillance, Epidemiology, and End Results program, were used to derive the incidence of hospitalizations due to chemotherapy-induced adverse effects per 100,000 cancer patients. Linear regression was performed to assess trends in incidence while logistic regression assessed trends in mortality. Multivariable analyses were used to adjust for age, gender, race, and primary source of payment. Results: Among the observed chemotherapy-induced adverse effects, the adjusted changes in incidence per year per 100,000 persons with cancer were observed for patients hospitalized due to anemia (4.9 [-24.6 – 34.5]), neutropenia (-23.7 [-45.4 – -2.1]), nausea and vomiting (-4.9 [-9.6 – -0.1]), and pneumocystis (-0.8 [-1.4 – -0.3]). Additionally, the adjusted decreases in the odds of mortality per year were observed for hospitalizations due to anemia (0.947 [0.946 – 0.948]), neutropenia (0.946 [0.944 – 0.948]), nausea and vomiting (0.949 [0.946 – 0.953]), and pneumocystis (0.964 [0.959 – 0.968]). Conclusion: Among this national cohort of cancer patients hospitalized due to chemotherapy-induced adverse effects, small but statistically significant decreases in hospitalization incidence and mortality may suggest that newer treatment strategies and practices may reduce adverse effects and their impact.


Vinall R, Chen Q, Talbott G, Hubbard N et al. Use of a genetically engineered mouse model and RNA-Seq to identify genes that can be regulated by mutant p53 in prostate cells following irradiation. AACR annual meeting, Washington DC, April 2017.

Abstract: Our group has previously demonstrated that the Trp53 R270H mutation can drive prostate cancer (CaP) initiation in a genetically engineered mouse model, and that the human equivalent, TP53 R273H, can promote development of castration resistant growth of LNCaP cells as well as resistance to commonly-used therapeutic agents. The primary objective of the current study was to identify genes that may contribute to the development of these gain-of-function phenotypes.

Wildtype mice and mice that were heterozygous or homozygous for the Trp53 R270H mutation (referred to as Trp53 +/+, Trp53 +/ R270H, or Trp53 R270H/R270H, respectively) that were ~3 months old were exposed to 5 Gy radiation to activate and stabilize p53, consequently increasing its expression. Mouse prostates were harvested 6 hours post-irradiation and either processed for subsequent histological/immunohistochemistry (IHC) analysis or snap-frozen for subsequent RNA extraction and transcriptome profiling with RNA-Sequencing (RNA-Seq) analysis. P53 expression was determined by IHC. RNA-Seq data were processed to quantify transcript levels and to assess differential gene expression between the 3 groups.

PIN lesions were observed in 3-month-old Trp53 R270H/R270H mice prostates, but not in Trp53 +/+ or Trp53 +/ R270H mice prostates. IHC analysis demonstrated that p53 was stabilized in the majority of prostate cells from Trp53 +/+, Trp53 +/ R270H, or Trp53 R270H/R270H mice 6 hours post-irradiation. RNA-Seq analysis of RNA isolated from irradiated mice prostates identified 1,444 genes that were differentially expressed in Trp53 +/+ versus Trp53 R270H/R270H mice prostate cells, and 796 genes that were differentially expressed in Trp53 +/+ versus Trp53 +/ R270H mice. Statistically significant differences in gene expression between the 3 groups were observed for 1,378 genes, including a number of p53 target genes, such as Cdkn1a, Bax, Bcl2, Kras, Mdm2, and Id4.

Our data identify multiple genes that may contribute to prostate cancer initiation and/or progression through p53 gain-of-function and loss-of-function mechanisms. It is possible that further analysis of these genes may lead to the development of new therapies and/or biomarkers for prostate cancer patients as well as guide the usage of currently available therapies in men at risk of developing CaP and CaP patients who harbor TP53 mutations.


Fitzpatrick LR, Talbott G, Mokrushin E, Woldemariam T. Ex Vivo Effects of Silymarin Fractions on Pro-inflammatory Cytokine Secretion from Colonic Strips of Mice with DSS-Induced Colitis. Digestive Disease Week annual meeting, Chicago IL, May 2017.

Abstract: Silymarin is an extract of milk thistle seeds. The silymarin complex consists of four major classes of flavonoligans: silibinin, silychristin, silydianin and isosilibinin. These compounds have both antioxidant and anti-inflammatory activities. Previously, we found that certain silymarin-derived fractions attenuated pro-inflammatory cytokine (TNF-α and IL-8) secretion from macrophage and colonic epithelial cell lines [Gastroenterology 150: S376-S377, 2016]. Methods: Silymarin fraction compositions were confirmed by (LC/MS) analyses. Silibinin and isosilibinin were obtained from a commercial source. Dextran Sulfate Sodium (DSS) was given to male C57BL/6 mice (n = 16) in the drinking water (2% concentration), for a six day period, in order to induce colitis. Control mice (n = 8) received water. The ex vivo effects of crude silymarin extract, two distinct silymarin fractions, as well as silibinin and isosilibinin (20 to 200 μg/ml concentration range) were tested in our 24 hour colonic culture system [Fitzpatrick et al., Inflammopharmacology, 2014]. We utilized ≈ 4 mm colonic strips (n = 4 to 7 per flavonoligan treatment group) from mice with DSS-induced colitis. The secretion of TNF-α and MIP-2 were determined in the cell culture media by ELISA. Some colonic strips were stimulated with IL-1β (10 ng/ml) plus IL-23 (10 ng/ml) to induce IL-17 secretion. This cytokine was measured with an ELISA kit. Results: Mice that were administered DSS showed clear evidence of colitis (enhanced diseases activity indices and reduced colon lengths). Ex vivo treatment with fraction 2 (containing mainly isosilibinin and silibinin), silibinin, or isosilibinin were most effective for inhibiting dual cytokine stimulated IL-17 secretion. Specifically, IL-17 values (pg/ml) were: 55±7 (Vehicle), 26±5 (fraction 5), 20±7 (crude extract), 13±5 (fraction 2), 11±5 (silibinin) and 9±2 (isosilibinin). All treatments significantly reduced (p < 0.05 vs. vehicle) IL-17 secretion. Fraction 2 and isosilibinin (at 200 μg/ml) also significantly (p< 0.05 vs. vehicle treatment) attenuated TNF-α secretion to the level found in colonic strips from non-DSS treated mice. Other silymarin-derived fractions and compounds also reduced TNF-α secretion, but not to the same degree. For attenuating MIP-2 secretion: the mean percent inhibition (compared to vehicle treatment) was: Fraction 2 (96%) = Isosilibinin (96%) > Silibinin (92%) > crude extract (75%) > fraction 5 (69%). Summary: A silibinin/isosilibinin containing fraction of silymarin, as well as these two compounds, prominently inhibited basal and stimulated pro-inflammatory cytokine secretion from colonic strips of mice with DSS-induced colitis. Conclusion: These data further contribute to the identification of optimal silymarin-derived anti-inflammatory flavonoligans, which can be used for follow-up in vivo testing in murine models of colitis.


Woldemariam TZ, Evans S, Ugbaja C, Owens D, Talbott G. Synergistic anti-tumor activity of sesquiterpene lactones and flavonoids: An in vitro study using human cancer cell lines. ASP 57th Annual Meeting, Portland OR, July 2017.

Abstract: In an effort to discover novel bioactive plant natural products with utility in the treatment of cancer, we generated and assessed variety of classes of compounds for possible in vitro cytotoxic activity against Human HT-29 colon carcinoma cells. Sesquiterpene lactones isolated from Taraxacum officinale (Dandelion) leaf and flavonoids from Glycyrrhiza uralensis (Licorice) root were found to show significant anti-tumor activities. Chemical and physical data for the active compounds, cytotoxic activity and the bioassay-guided fractionation of the methanolic extracts will be presented.

Bioactivity-guided fractionation of the methanol extracts afforded several fractions and sesquiterpene lactones and flavonoids which showed significant reductions in cell viability were observed. Observation under a microscope suggested the cancer cells were dying by an apoptotic mechanism and the exact mechanism of cell death is currently being investigated biochemically. Combinations of fractions containing the sesquiterpene lactones and flavonoids showed improved IC50 values and the results of the synergistic anti-tumor activity of the fractions as well as pure compounds will be presented.

These findings highlight the importance of the use of combining different compounds to augment direct synergistic therapeutic effects when active constituents are combined within and between many medicinal herbs.


Woldemariam TZ, Ma O, Stephenson C, Gostantian A, Talbott G. Evaluation of the anti-tumour activity of Panax Ginseng and Tanacetum Parthenium. ASP 57th Annual Meeting, Portland OR, July 2017.

Abstract: A library of compounds derived from variety of plants were generated and assessed for possible in vitro cytotoxic activity against Human HT-29 colon carcinoma cells. Bioactivity-guided fractionation of the methanol extracts of these plants afforded several fractions and compounds which showed significant reductions in cell viability were observed. Compounds isolated from Panax Ginseng root and Tanacetum Parthenium leaf in particular were found to show significant anti-tumor activities. The most active purified fractions isolated from both Panax Ginseng root and Tanacetum Parthenium leaves contain flavonoids. Efforts are underway to identify and determine the efficacy of individual flavonoids. Observation under a microscope suggested the cancer cells were dying by an apoptotic mechanism and the exact mechanism of cell death is currently being investigated biochemically. Chemical and physical data for the active compounds, cytotoxic activity and the bioassay-guided fractionation of the methanolic extracts will be presented.

The observed potent anti-tumor activity of flavonoids from both Tanacetum Parthenium and Panax Ginseng make attractive drug candidates for further testing in other tumor cell lines.


Woldemariam TZ, Shakarian P, Alajajian RM, Le K. Evaluating the efficacy of different solvent systems for selective extraction of carotenoids from Lycium Barbarum. ASP 57th Annual Meeting, Portland OR, July 2017.

Abstract: The extraction efficacy of different solvent systems was investigated for extraction of carotenoids from Lycium barbarum, known as Goji berries. Biocompatible extraction solvents were used the extract in the liquid form directly in pharmaceutical formulations that are at least substantially non-toxic and acceptable for human use, topically or orally. Goji berries are full of nutrients including amino acids, carotenoids, and polysaccharides. The optimized solvents selectively extracted the carotenoids from minerals, vitamin C, amino acids, and polysaccharides.

The solvents could offer an environmentally friendly way to isolate the plant compounds without the need for toxic organic solvents. The solvents produced yields similar to those of typical organic solvents including ethanol, ethyl acetate and acetone. The individual carotenoids were further isolated with flash chromatography and identified with nuclear magnetic resonance and mass spectrometry. Chemical and physical data of the extraction and isolation procedure will be presented.

These data further contribute to the identification of optimal and selective extraction and isolation of procedure, which can be used for follow-up in vivo oral and topical administration of carotenoids.


Clark S, Khansari PS, Atef E, Elkeeb R, Hassell K. Adapting Supplemental Instruction (SI) methods to a Doctor of Pharmacy program with curriculum-wide Team-Based Learning (TBL) pedagogy. The Association of Colleges for Tutoring and Learning Assistance Conference, Sacramento, California, April 2017


Presentation Description

On-time graduation rates and degree completion are important goals for colleges and universities, including healthcare programs. To support early career professional pharmacy students, we have adapted traditional undergraduate supplemental instruction (SI) methods to a Doctor of Pharmacy program for which team-based learning (TBL) is used across the curriculum.

What do you hope to accomplish (session outcomes)?

On-time graduation rates and completion are important goals for colleges, including professional pharmacy programs. Early student support programs, such as supplemental instruction (SI), can promote student success. We hope to share the methods by which we have adapted the traditional undergraduate SI approach to a Doctor of Pharmacy (PharmD) program, including integrating team-based learning (TBL) techniques.

We will share with the audience how our California Northstate University College of Pharmacy SI (CSI) student leaders apply SI and TBL techniques. We also will outline how Department Chairs and Academic Deans can support CSI for the classes in their departments, and how teaching faculty can help the CSI Student Leaders target their sessions to the most difficult material, while still allowing CSI Student Leaders full autonomy. We will deliver this program using TBL active learning methods with the aim of encouraging audience engagement, gathering input, and allowing dissemination of ideas at the end of the program.

What is the significance of your topic?

Despite the success of Supplemental Instruction (SI) in undergraduate and some professional programs, few reports exist on adapting a formal SI approach to PharmD education. We report here how many of the traditional methods of SI can be adapted to a PharmD program. We will discuss the methods we have used to assure the success and sustainability of the program, including obtaining high participation rates, as well as the benefit to the students and the student leaders.


Clark S, Khansari PS, Jungnickel PW, Maize DF, Hassell K. Adaptation of Supplemental Instruction (SI), a pre-remediation, peer-led academic assistance program, to PharmD Programs. American Association of Colleges of Pharmacy Annual Meeting, Nashville TN, July 2017.


Program Purpose: Supplemental Instruction (SI) is a pre-remediation academic assistance program focused on high-risk courses instead of struggling students. This program will discuss how SI has been applied to three different PharmD programs.

Background: According to Maize, et al., (AJPE 2010), preventive measures are divided into three categories: admissions standards, early detection, and academic assistance programs. PharmD academic assistance programs include remediation and pre-remediation. Remediation occurs after a student has failed a course, whereas pre-remediation aims to prevent failure. In that respect, pre-remediation strategies focus on facilitating academic progression, which is an important component of the ACPE 2016 Standard 17. One common pre-remediation program is Supplemental Instruction (SI). SI is used in undergraduate programs across the US, as well as international colleges and universities, to target high-risk courses. In a review of remediation and pre-remediation programs, SI was considered appropriate for PharmD programs (Maize, et al., 2010). Although certain aspects of traditional SI are not amenable to PharmD programs, many core aspects can be maintained professional PharmD Programs (Mosley, et al, 2013).

Session Goals: Our session will provide an overview of the SI, as well as a review of modified SI programs at 3 different PharmD programs. These programs, combined, include a total of 20 years of experience offering SI. We will use active learning strategies to assist the audience in adapting SI for their own high-risk courses for which they would like to develop a pre-remediation peer-lead SI program.

History and Principles of Traditional SI Programs: SI was developed by Deanna C. Martin, PhD in 1973 at the University of Missouri, Kansas City (UMKC). It is now is used widely in undergraduate programs across the US, as well as in educational institutions worldwide, including the UK, EU, Australia, Canada and South Africa. (Marcia Ody, Teaching and Learning Manager, The University of Manchester, Oxford Road, Manchester, M13 9PL, July 2017,on This email address is being protected from spambots. You need JavaScript enabled to view it..)


Maize DF, Fuller SH, Hritcko PM, Matsumoto RR, Soltis DA, Taheri RR, Duncan W., A review of remediation programs in pharmacy and other health professions. Am J Pharm Educ. 2010;74(2):25

Mosley AT, Maize DF, LaGrange LP, Pharmacy students’ perception of a modified supplemental instruction program. Curr Pharm Teach Learn 2013;5:175-179.


Khansari PS, Clark S, Hassell K. (2017) Enhancing student learning through effective feedback. Pharmacy Education Conference, Prato Italy. July 2017


Objective: To implement strategies that enhances feedback effectiveness in pharmacy education. Design: California Northstate University College of Pharmacy (CNUCOP) utilizes Team-Based-Learning (TBL), a small group learning technique as its exclusive pedagogy. Although TBL inherently encompasses feedback through team and class discussion and peer evaluation, the faculty at CNUCOP have implemented additional strategies to enhance feedback effectiveness. Assessment: One such strategy is the implementation of a team review exam prior to a major summative exam. The team exam has a similar format to individual exams, with the exception that teammates work together to answer questions and discuss answers. Our data suggest that students perceived taking a team exam as an effective approach to identify knowledge gaps and areas for improvement. Another strategy to provide effective feedback is a short meeting with each student after a summative exam to review areas requiring improvement. Although this is a short meeting, it enriches the students’ commitment to improve their academic performance, evidenced by an increase in requests for supplemental instruction from their peers or instructors. Furthermore, students are given feedback and receive training on giving feedback to their peers when they develop a formal case study presentation in their Pathophysiology/Pharmacology class. Students are instructed to provide constructive, informative feedback to their fellow co-presenters and to other student presenters. Conclusion: Providing timely and effective feedback is an instrumental approach to improve learning outcome.


1. Hattie, J., Timperley H., 2007. The Power of Feedback. Review of Educational Research, 77.

2. Ofstad, W. and L.J. Brunner, Team-based learning in pharmacy education. Am J Pharm Educ, 2013. 77(4): Article 70, p. 1-20.


McDowell JA., Pauli MW, Le J, Bakkie KK, Nguyen JD, Tran DCN, Khansari PS, Clark S, Tran HT. CNUCOP student leadership: empowering students for peer leadership. American Association of Colleges of Pharmacy Annual Meeting, Nashville TN, July 2017.


Empowering students to become effective leaders is a vital part of the PharmD program at California Northstate University College of Pharmacy. Our College strives to create an environment for students to develop and practice their leadership skills. The Student Ambassadors Advisory Council (SAAC) and Rho Chi/CNU Supplemental Instruction (Rho Chi/CSI) are major student-led group on campus that contribute to student learning and success.

Each fall the new SAAC members are selected by current members, based on their candidates’ understanding of effective leadership qualities. SAAC leaders run the student-centered component of our interview day for PharmD applicants. The SAAC team assigns and facilitates key student roles in the interview process. They also represent the student body for accreditation site visits and highlight the institution in open house events, tours and orientation.

Rho Chi/CSI provides student-led academic assistance through formal, regularly scheduled review sessions. These opportunities promote student leadership in academics and teamwork, as well as provide exposure to academic careers. As CSI Leaders are among our strongest students academically, they model professionalism and academic excellence for the P1 class.

These practices are well-aligned with two of our six fundamental Co-Curricular Learning Outcomes (# 2: Professionalism and Advocacy and # 6: Service and Leadership). These opportunities help student leaders develop collaborative leadership and mentoring skills to accomplish shared goals. The effectiveness of these leadership training programs was demonstrated in the recent Western Association of Schools and Colleges accreditation report where CNU received commendations as having an “…intentional spirit of innovative educational practices.”


Kaur S. Implementation of Self and Peer Evaluation Process in Didactic Pharmacy Curriculum. American Association of Colleges of Pharmacy Annual Meeting, Nashville TN, July 2017.


Program Purpose:

As healthcare professionals, we are constantly working in a team and in our pharmacy curriculum, we give our students the tools necessary for team building and activities to become an effective member of the interprofessional team. Being part of a team also takes into account being able to reflect on one’s own and teammates behaviors which allows the team to be either a high functioning team or a low functioning team. Providing effective and constructive feedback is a skill that can aid in making a person an effective teammate which can lead to personal and professional growth. The purpose of this session is to sample a successful self and peer evaluation process in didactic pharmacy curriculum that allows pharmacy students an opportunity to reflect and improve on their behaviors to increase self-awareness.

Program Experience:

As the Director of Assessment at California Northstate University, we have successfully implemented the self and peer evaluation program in the didactic pharmacy curriculum. After literature search on best practices to capture behaviors of students that aids them in becoming effective teammates, we adopted the Comprehensive Assessment of Team Member Effectiveness (CATME), behaviorally anchored rating scale, to conduct self and peer evaluations and rating team processes in Fall of 2015. Five behaviors the tool asks the participants to reflect upon include contributing to the team's work, interactive with teammates, keeping the team on track, expecting quality, and having relevant knowledge, skills and abilities.

The process of self and peer evaluation involves comprehensive student training during orientation on providing effective feedback, opportunities for students to work in teams for a semester including utilization of team contracts, administering mid-semester formative CATME self and peer evaluations followed by end of the semester summative CATME self and peer evaluations. The formative non-punitive evaluations are run during mid-semester and results are disseminated to the students in a timely fashion so they can reflect on their behaviors and give them an opportunity to both keep the positive behaviors as well as improve on the behaviors that they were rated low on. It also allows students to visualize their behaviors in relationship to the aggregate peer's results utilizing a Likert-scale. At the end of the semester, students complete the same summative evaluation which is a graded exercise in an attempt to hold students accountable for being either an effective or non-effective team member. We have successfully run this program for over a year and we have received positive feedback from students during focused group discussions.

California Northstate University College of Pharmacy ♦ 9700 West Taron Drive ♦ Elk Grove, CA 95757 ♦ Phone: (916) 686-7400

CNSU logo


Contact Us